Jasper Therapeutics, Inc., a biotechnology company focused on
hematopoietic cell transplant therapies, and Amplitude Healthcare
Acquisition Corporation (Nasdaq: AMHCU), a special purpose
acquisition company (SPAC) sponsored by affiliates of Avego
Management, LLC and Metalmark Capital, today announced that
Lawrence Klein, Ph.D., and Chris Nolet will be appointed to Jasper
Therapeutics’ board of directors, effective upon closing of the
pending merger between the parties. Mr. Nolet will assume the role
of Audit Committee Chair.
“We are pleased to appoint Lawrence and Chris to the Jasper
board of directors to add additional expertise to the team in
cellular and gene therapy development and to build a leading public
biotechnology company,” said Bill Lis, executive chairman and chief
executive officer of Jasper Therapeutics. “We look forward to their
input and guidance as we advance the clinical development of
JSP191, our anti-CD117 monoclonal antibody, as a targeted,
non-toxic conditioning agent, and our novel engineered stem cell
platform, which aims to expand the number of patients who could
benefit from allogeneic and autologous gene edited hematopoietic
stem cell therapy.”
Dr. Klein currently serves as chief operating officer at CRISPR
Therapeutics, where he previously served as senior vice president
and head of strategy and business development. Before joining
CRISPR, he was an associate partner at McKinsey & Company,
where he was a leader in the biotech practice and served a number
of biotech companies on a wide range of topics from strategy to
operations. He earned a B.S. in biochemistry and physics from the
University of Wisconsin-Madison and a Ph.D. in biophysics from
Stanford University.
Mr. Nolet has extensive experience as a long-time audit partner
and business advisor in the life sciences industry. He currently
serves on the boards of three publicly-traded life science
companies and the board a life science industry organization. He is
the former West Region Life Sciences Industry Leader and Partner at
Ernst & Young (EY), having retired in June 2019 after more than
38 years in the profession. In addition to serving clients, his
responsibilities included leading the West Region EY Life Sciences
Industry Group and serving as a member of the Global EY Life
Sciences Executive Leadership Group, which established policies and
operating strategies for the EY Life Sciences practice worldwide.
Prior to joining EY, Mr. Nolet was a partner at
PricewaterhouseCoopers, where he led the life sciences practice in
the western U.S. He holds a B.S. in accounting from San Diego State
University and is a certified public accountant in California
(retired).
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the
development of novel curative therapies based on the biology of the
hematopoietic stem cell. The company is advancing two potentially
groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody,
is in clinical development as a conditioning agent that clears
hematopoietic stem cells from bone marrow in patients undergoing a
hematopoietic cell transplantation. It is designed to enable safer
and more effective curative allogeneic and autologous hematopoietic
cell transplants and gene therapies. In parallel, Jasper
Therapeutics is advancing its preclinical engineered hematopoietic
stem cell (eHSC) platform, which is designed to overcome key
limitations of allogeneic and autologous gene-edited stem cell
grafts. Both innovative programs have the potential to transform
the field and expand hematopoietic stem cell therapy cures to a
greater number of patients with life-threatening cancers, genetic
diseases and autoimmune diseases than is possible today. For more
information, please visit us at jaspertherapeutics.com.
About Amplitude Healthcare Acquisition Corporation
Amplitude was founded by Avego and Metalmark to seek innovative
private life sciences company acquisition targets. We leverage our
management and board’s reputation, experience, and track record of
making investments and creating value in the industry. We have a
strong history of building and growing companies as constructive
and trustworthy partners. For more information, please visit:
https://www.amplitudehealthcare.com.
Forward Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
the proposed business combination between Jasper Therapeutics, Inc.
and Amplitude Healthcare Acquisition Corporation, the proposed
appointment of Lawrence Klein, Ph.D., and Chris Nolet to the Jasper
Therapeutics’ board of directors, effective upon closing of the
pending merger between the parties and Jasper Therapeutics’
products, technologies and prospects. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “forecast,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions (including the negative versions
of such words or expressions). Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including but not
limited to: (i) the risk that the proposed business combination may
not be completed in a timely manner or at all; (ii) the failure to
satisfy the conditions to the consummation of the proposed business
combination; (iii) the effect of the announcement or pendency of
the proposed business combination on Jasper Therapeutics’ business
relationships, performance, and business generally; and (iv) the
ability to implement business plans, forecasts, and other
expectations after the completion of the proposed business
combination, and identify and realize additional opportunities. The
foregoing list of factors is not exhaustive. You should carefully
consider the foregoing factors and the other risks and
uncertainties described in Amplitude Healthcare Acquisition
Corporation final proxy statement/information statement/prospectus
contained in the Form S-4 registration statement described below,
including those under “Risk Factors” therein, Quarterly Reports on
Form 10-Q and other documents filed by Amplitude Healthcare
Acquisition Corporation from time to time with the U.S. Securities
and Exchange Commission (the “SEC”). These filings identify and
address other important risks and uncertainties that could cause
actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Jasper
Therapeutics, Inc. and Amplitude Healthcare Acquisition Corporation
assume no obligation and, except as required by law, do not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Neither
Jasper Therapeutics, Inc. nor Amplitude Healthcare Acquisition
Corporation gives any assurance that either Jasper Therapeutics,
Inc. or Amplitude Healthcare Acquisition Corporation will achieve
its expectations.
Additional Information and Where to Find It
In connection with the proposed business combination between
Jasper Therapeutics, Inc. and Amplitude Healthcare Acquisition
Corporation, the registration statement on Form S-4 has been
declared effective by the SEC. That registration statement includes
the related proxy statement and prospectus of Amplitude Healthcare
Acquisition Corporation with respect to Amplitude Healthcare
Acquisition Corporation’s special meeting of stockholders.
Amplitude Healthcare Acquisition Corporation’s stockholders and
other interested persons are advised to read the registration
statement and the related proxy statement/prospectus and any
documents filed in connection therewith, as these materials will
contain important information about Jasper Therapeutics, Inc.,
Amplitude Healthcare Acquisition Corporation and the proposed
business combination. The definitive proxy statement and related
materials have been mailed to Amplitude Healthcare Acquisition
Corporation’s stockholders who were holders of record as of the
close of business on August 20, 2021 .
Investors and security holders may obtain free copies of the
proxy statement/information statement/prospectus and all other
relevant documents filed with the SEC by Amplitude Healthcare
Acquisition Corporation through the website maintained by the SEC
at www.sec.gov. In addition, the documents filed by Amplitude
Healthcare Acquisition Corporation may be obtained free of charge
by directing a request to Amplitude Healthcare Acquisition
Corporation, 1177 Avenue of the Americas, Fl 40, New York, New York
10036.
Disclaimer
This communication is for informational purposes only and is
neither an offer to purchase, nor a solicitation of an offer to
sell, subscribe for or buy, any securities or the solicitation of
any vote in any jurisdiction pursuant to the proposed business
combination or otherwise, nor shall there be any sale, issuance or
transfer or securities in any jurisdiction in contravention of
applicable law. No offer of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210920005843/en/
Jasper Therapeutics Contacts Lily Eng (media) Real
Chemistry 206-661-8627 leng@realchemistry.com
Jeet Mahal (investors) Jasper Therapeutics 650-549-1403
jmahal@jaspertherapeutics.com
Amplitude Contact
IR@amplitudehealthcare.com
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024